{"id":"gp40321","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Dizziness"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"GP40321 acts as a selective serotonin receptor antagonist, which helps to modulate the activity of serotonin in the body. This mechanism is thought to contribute to its therapeutic effects.","oneSentence":"GP40321 is a small molecule that targets the serotonin receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:14:17.141Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment-resistant depression"}]},"trialDetails":[{"nctId":"NCT07070752","phase":"PHASE3","title":"Evaluation of Insulin Glulisine (GP40321) Compared to Insulin Glulisine (Apidra® SoloStar®) in Type 1 Diabetes Mellitus Patients","status":"COMPLETED","sponsor":"Geropharm","startDate":"2023-04-14","conditions":"Type 1 Diabetes Mellitis","enrollment":224}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["insulin glulisine"],"phase":"phase_3","status":"active","brandName":"GP40321","genericName":"GP40321","companyName":"Geropharm","companyId":"geropharm","modality":"Small molecule","firstApprovalDate":"","aiSummary":"GP40321 is a small molecule that targets the serotonin receptor. Used for Treatment-resistant depression.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}